Prescription medicine
Glecaprevir and pibrentasvir Brand names: Mavyret
Glecaprevir and pibrentasvir (Mavyret) is a prescription medicine with an FDA approval on record since 2017. No generic is listed; pharmacies paid $152.98 per Mavyret 100-40 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
- Boxed warning
Check it at the source: the glecaprevir and pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.); the NDA 209394 record on Drugs@FDA; every glecaprevir and pibrentasvir label on DailyMed.
Highlights of the record
FDA label of June 25, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV.
Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions ( 5.1 )]. WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death.
Used for
From the label: indications and usageMAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).
Forms and strengths
- 20 mg / 50 mg
- 40 mg / 100 mg
Film-coated tablet; pellet.
On the market
- Earliest approval on file
- August 3, 2017 Mavyret, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- December 24, 2036 Mavyret tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $152.98 per tablet Mavyret 100-40 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 10,923 through July 30, 2026
What is glecaprevir and pibrentasvir used for?
From the label: indications and usageMAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14 )]. […]
Conditions named in the indications of glecaprevir and pibrentasvir's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Hepatitis C Virus NS3/4A Protease Inhibitor and Hepatitis C Virus NS5A Inhibitor.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
What does the patient leaflet for glecaprevir and pibrentasvir say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about MAVYRET?MAVYRET can cause serious side effects, including: Hepatitis B virus reactivation. Before starting treatment with MAVYRET, your healthcare provider will do blood tests to check for hepatitis B virus infection. If you have ever had hepatitis B virus infection, the hepatitis B virus could become active again during or after treatment for hepatitis C virus with MAVYRET. Hepatitis B virus that becomes active again (called reactivation) may cause serious liver problems including liver failure and death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop taking MAVYRET. For more information about side effects, see the section “What are the possible side effects of MAVYRET?”
From the patient leaflet: How should I store MAVYRET?Store MAVYRET at or below 86°F (30°C). Keep MAVYRET in its original package until you are ready to take it. Keep MAVYRET and all medicines out of the reach of children.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
Is there a generic for glecaprevir and pibrentasvir (Mavyret)?
No generic glecaprevir and pibrentasvir is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 10 patents for Mavyret tablets: the compound patent runs to June 5, 2035 (pediatric exclusivity to December 5, 2035), and the last listed entry to December 24, 2036. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2017 earliest approval on file
- 2036 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for glecaprevir and pibrentasvir (Mavyret)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $152.98 per Mavyret 100-40 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Mavyret 100-40 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Mavyret 100-40 mg tablet | Brand | $152.98 per tablet | $4,589.50 | +0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the glecaprevir and pibrentasvir label say about other medicines?
The glecaprevir and pibrentasvir label names 42 other medicines in its interaction, contraindication or warning sections. The labels of 15 other medicines name glecaprevir and pibrentasvir. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Abacavir | drug interactions | Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam … |
| Amlodipine | drug interactions | Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam … |
| Atazanavir | contraindications | MAVYRET is contraindicated with atazanavir or rifampin [see Drug Interaction ( 7.3 ) and Clinical Pharmacology ( 12.3 )]. |
| Atorvastatin | drug interactions | Concomitant Drug Class/Drug Name: Atorvastatin Lovastatin Simvastatin; Effect on Concentration: ↑ atorvastatin ↑ lovastatin ↑ simvastatin; Clinical Comments: Coadministration may increase the concentration of atorvastatin, lovastatin, and simvastatin. … |
| Buprenorphine and naloxone | drug interactions | See Clinical Pharmacology, Tables 10 and 11 . ↑= increase; ↓= decrease; ↔ = no effect 7.4 Medication-Assisted Treatment (MAT) for Opioid Use Disorder No buprenorphine/naloxone or methadone dosage adjustment is required when used concomitantly with MAVYRET. |
| Caffeine | drug interactions | Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam … |
| Carbamazepine | drug interactions | DRUG INTERACTIONS Carbamazepine, efavirenz, and St. John’s wort may decrease concentrations of glecaprevir and pibrentasvir. |
| Cobicistat | drug interactions | Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam … |
| Cyclosporine | drug interactions | Concomitant Drug Class/Drug Name: Cyclosporine; Effect on Concentration: ↑ glecaprevir ↑ pibrentasvir; Clinical Comments: MAVYRET is not recommended for use in patients requiring stable cyclosporine doses > 100 mg per day. |
| Dabigatran | drug interactions | Concomitant Drug Class/Drug Name: Dabigatran etexilate; Effect on Concentration: ↑ dabigatran; Clinical Comments: If MAVYRET and dabigatran etexilate are coadministered, refer to the dabigatran etexilate prescribing information for dabigatran etexilate dose modifications in combination with P-gp inhibitors in the … |
| Darunavir | drug interactions | Concomitant Drug Class/Drug Name: Darunavir Lopinavir Ritonavir; Effect on Concentration: ↑ glecaprevir ↑ pibrentasvir; Clinical Comments: Coadministration is not recommended. |
| Dextromethorphan | drug interactions | Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam … |
| Digoxin | drug interactions | Concomitant Drug Class/Drug Name: Digoxin; Effect on Concentration: ↑ digoxin; Clinical Comments: Measure serum digoxin concentrations before initiating MAVYRET. Reduce digoxin concentrations by decreasing the dose by approximately 50% or by modifying the dosing frequency and continue monitoring. |
| Dolutegravir | drug interactions | Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam … |
Every other medicine the glecaprevir and pibrentasvir label names
| Medicine named | Section | What the label says |
|---|---|---|
| Efavirenz | drug interactions | DRUG INTERACTIONS Carbamazepine, efavirenz, and St. John’s wort may decrease concentrations of glecaprevir and pibrentasvir. |
| Emtricitabine | drug interactions | … caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or … |
| Felodipine | drug interactions | … elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives … |
| Fluvastatin | drug interactions | Concomitant Drug Class/Drug Name: Fluvastatin Pitavastatin; Effect on Concentration: ↑ fluvastatin ↑ pitavastatin; Clinical Comments: Coadministration may increase the concentrations of fluvastatin … |
| Lamivudine | drug interactions | … cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole … |
| Lamotrigine | drug interactions | … emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole, raltegravir … |
| Losartan | drug interactions | … estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir … |
| Lovastatin | drug interactions | Concomitant Drug Class/Drug Name: Atorvastatin Lovastatin Simvastatin; Effect on Concentration: ↑ atorvastatin ↑ lovastatin ↑ simvastatin; … |
| Methadone | drug interactions | … Treatment (MAT) for Opioid Use Disorder No buprenorphine/naloxone or methadone dosage adjustment is required when used concomitantly with MAVYRET. |
| Midazolam | drug interactions | … of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus … |
| Naltrexone | drug interactions | There is insufficient information to make a recommendation regarding the concomitant use of naltrexone with MAVYRET. |
| Norethindrone | drug interactions | … or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir … |
| Omeprazole | drug interactions | … losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate … |
| Phenytoin | drug interactions | Carbamazepine, phenytoin, efavirenz, and St. John’s wort may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect of MAVYRET. |
| Pitavastatin | drug interactions | Concomitant Drug Class/Drug Name: Fluvastatin Pitavastatin; Effect on Concentration: ↑ fluvastatin ↑ pitavastatin; Clinical Comments: Coadministration may increase the concentrations of fluvastatin … |
| Pravastatin | drug interactions | Concomitant Drug Class/Drug Name: Pravastatin; Effect on Concentration: ↑ pravastatin; Clinical Comments: Coadministration may increase the concentration of pravastatin. … |
| Raltegravir | drug interactions | … norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan. |
| Rifampin | contraindications | MAVYRET is contraindicated with atazanavir or rifampin [see Drug Interaction ( 7.3 ) and Clinical Pharmacology ( 12.3 )]. |
| Rilpivirine | drug interactions | … norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan. |
| Ritonavir | drug interactions | Concomitant Drug Class/Drug Name: Darunavir Lopinavir Ritonavir; Effect on Concentration: ↑ glecaprevir ↑ pibrentasvir; Clinical Comments: Coadministration is not recommended. |
| Rosuvastatin | drug interactions | Concomitant Drug Class/Drug Name: Rosuvastatin; Effect on Concentration: ↑ rosuvastatin; Clinical Comments: Coadministration may significantly increase the concentration of rosuvastatin. … |
| Simvastatin | drug interactions | Concomitant Drug Class/Drug Name: Atorvastatin Lovastatin Simvastatin; Effect on Concentration: ↑ atorvastatin ↑ lovastatin ↑ simvastatin; … |
| Sofosbuvir | drug interactions | … progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan. |
| Tacrolimus | drug interactions | … contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan. |
| Tenofovir alafenamide | drug interactions | … contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan. |
| Tenofovir disoproxil | drug interactions | … raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan. |
| Valsartan | drug interactions | … tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan. |
| Warfarin | drug interactions | Frequent monitoring of relevant laboratory parameters (e.g. International Normalized Ratio [INR] in patients taking warfarin, blood glucose levels in diabetic patients) or drug concentrations of … |
Other labels that name glecaprevir and pibrentasvir
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
What do FAERS reports show for glecaprevir and pibrentasvir?
The FDA Adverse Event Reporting System holds 10,923 reports that list glecaprevir and pibrentasvir among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 289 are coded as a death and 1,317 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2019 (3,713, against a median of 437 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as glecaprevir and pibrentasvir?
6 other medicines are given the same way (oral) and in the same FDA class as glecaprevir and pibrentasvir or labeled mainly for the same use (hepatitis c), the same class first. Hepatitis C lists all 8 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Ledipasvir and sofosbuvir | Hepatitis C | none listed | n/a | No current entry |
| Sofosbuvir and velpatasvir | Hepatitis C | none listed | $278.03 per unit 400-100 | No current entry |
| Elbasvir and grazoprevir | Hepatitis C | none listed | n/a | A presentation being discontinued |
| Sofosbuvir and velpatasvir and voxilaprevir | Hepatitis C | none listed | n/a | No current entry |
| Ribavirin | Hepatitis C | 1 labeler | $0.451 per tablet 200 mg tablet | No current entry |
| Sofosbuvir | Hepatitis C | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as glecaprevir and pibrentasvir
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to glecaprevir and pibrentasvir
- 6 medicines for the same use
- Other hepatitis c virus ns3/4a protease inhibitors
- the pharmacologic class, with prices and generics
- Glecaprevir and pibrentasvir side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other